Trustcore Financial Services LLC boosted its holdings in shares of Amgen, Inc. (NASDAQ:AMGN) by 7.6% in the 2nd quarter, according to its most recent Form 13F filing with the SEC. The firm owned 1,345 shares of the medical research company’s stock after buying an additional 95 shares during the period. Trustcore Financial Services LLC’s holdings in Amgen were worth $248,000 as of its most recent SEC filing.
A number of other large investors have also bought and sold shares of the stock. Capital Financial Planning LLC bought a new stake in Amgen during the fourth quarter worth about $27,000. Arbor Wealth Management LLC lifted its stake in Amgen by 154.5% during the second quarter. Arbor Wealth Management LLC now owns 168 shares of the medical research company’s stock worth $31,000 after purchasing an additional 102 shares during the last quarter. Next Capital Management LLC bought a new stake in Amgen during the fourth quarter worth about $33,000. C J Advisory Inc bought a new stake in Amgen during the first quarter worth about $40,000. Finally, Clarfeld Financial Advisors LLC bought a new stake in Amgen during the fourth quarter worth about $41,000. 77.43% of the stock is owned by institutional investors.
AMGN has been the subject of several research analyst reports. Cowen reaffirmed a “buy” rating and set a $229.00 price target on shares of Amgen in a research note on Wednesday, May 1st. BidaskClub upgraded Amgen from a “sell” rating to a “hold” rating in a report on Thursday, August 1st. Royal Bank of Canada reiterated a “neutral” rating and issued a $192.00 price objective on shares of Amgen in a report on Tuesday, May 21st. JPMorgan Chase & Co. reiterated a “hold” rating and issued a $190.00 price objective on shares of Amgen in a report on Wednesday, May 15th. Finally, Zacks Investment Research downgraded Amgen from a “buy” rating to a “hold” rating in a report on Monday, April 15th. Eight equities research analysts have rated the stock with a hold rating and ten have given a buy rating to the company’s stock. Amgen has a consensus rating of “Buy” and a consensus target price of $210.41.
Shares of AMGN traded down $0.36 during mid-day trading on Tuesday, reaching $181.14. The company had a trading volume of 1,004,048 shares, compared to its average volume of 2,851,860. The company has a debt-to-equity ratio of 2.58, a current ratio of 2.89 and a quick ratio of 2.60. The stock’s 50-day moving average is $181.47. Amgen, Inc. has a 52 week low of $166.30 and a 52 week high of $210.19. The stock has a market capitalization of $108.85 billion, a P/E ratio of 12.58, a price-to-earnings-growth ratio of 2.20 and a beta of 1.19.
Amgen (NASDAQ:AMGN) last issued its quarterly earnings results on Tuesday, July 30th. The medical research company reported $3.97 EPS for the quarter, topping analysts’ consensus estimates of $3.58 by $0.39. Amgen had a return on equity of 76.17% and a net margin of 33.78%. The firm had revenue of $5.87 billion for the quarter, compared to analysts’ expectations of $5.67 billion. During the same period in the previous year, the firm posted $3.83 EPS. The business’s revenue for the quarter was down 3.1% compared to the same quarter last year. On average, research analysts anticipate that Amgen, Inc. will post 14.23 earnings per share for the current year.
The business also recently declared a quarterly dividend, which will be paid on Friday, September 6th. Stockholders of record on Thursday, August 15th will be given a $1.45 dividend. The ex-dividend date of this dividend is Wednesday, August 14th. This represents a $5.80 dividend on an annualized basis and a dividend yield of 3.20%. Amgen’s dividend payout ratio is currently 40.28%.
Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. It offers products for the treatment of oncology/hematology, cardiovascular, inflammation, bone health, and neuroscience. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta, a pegylated protein to treat cancer patients; Prolia to treat postmenopausal women with osteoporosis; Aranesp to treat anemia; Xgeva for skeletal-related events prevention; Sensipar/Mimpara products to treat sHPT in chronic kidney disease; and EPOGEN to treat a lower-than-normal number of red blood cells.
Read More: Dead Cat Bounce
Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen, Inc. (NASDAQ:AMGN).
Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.